2200 Pennsylvania Avenue, NW
District of Columbia
We are a science and technology innovator committed to helping our customers solve complex challenges, and improving quality of life around the world.
A global family of more than 20 operating companies, we drive meaningful innovation in some of today’s most dynamic, growing industries. With operating companies based around the world—from California to Copenhagen—our groundbreaking businesses transform the fields of diagnostics, life sciences, dental care, and environmental and applied solutions by:
• improving patient health through powerful tools that increase diagnostic confidence
• advancing scientific research to illuminate the causes of disease and pave the way to new, life-saving treatments
• improving dental outcomes and patient care around the world
• ensuring the freshness, dosages and safety of food, pharmaceuticals and consumer goods
• protecting our global water supply and promoting environmental stewardship
We are a team of 59,000 dedicated associates who are Helping Realize Life’s Potential every day by bringing our diverse skills, backgrounds, and perspectives together to make a difference.
We are a diverse team of people and operating companies, each with unique missions and challenges. Yet, we are united by Our Shared Purpose, which directs how we live out every day to achieve our most ambitious goals.
Our Shared Purpose confirms our commitment to helping our customers achieve amazing things and the high standards by which we measure our own success. We innovate forward-looking technologies to solve our customers’ most complex challenges. We are their agents of possibility.
66 articles with Danaher
Danaher Announces Closing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering - March 1, 2019
Danaher Corporation announced that it has closed concurrent offerings of 12,100,000 shares of common stock at a price to the public of $123.00 per share and 1,650,000 shares of 4.75% Series A Mandatory Convertible Preferred Stock at a price to the public of $1,000 per share.
Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering
Danaher Corporation announced that it has priced concurrent offerings of 11,000,000 shares of common stock at a price to the public of $123.00 per share and 1,500,000 shares of 4.75% Series A Mandatory Convertible Preferred Stock at a price to the public of $1,000 per share.
GE announced a definitive agreement to sell its BioPharma business to Danaher Corporation for a total consideration of $21.4 billion, including $21 billion in cash as well as Danaher’s assumption of certain pension liabilities.
Danaher Corporation announced that it has entered into a definitive agreement with General Electric Company to acquire the Biopharma business of GE Life Sciences for a cash purchase price of approximately $21.4 billion.
Shares of General Electric jumped as much as 13 percent in trading this morning after Danaher Corporation announced it was acquiring the conglomerate’s biopharma business, GE Biopharma, for $21.4 billion.
Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Thomas P. Joyce, Jr., will comment tomorrow on the Company's fourth quarter 2018 performance in a presentation at the J.P. Morgan Healthcare Conference in San Francisco, California at 8:00 a.m. PT.
Danaher Corporation announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 8, 2019 at 8:00 a.m. PT.
Ahead of its annual investor and analyst meeting to be held in New York City, Danaher Corporation initiated its 2019 outlook.
Danaher Corporation announced today that its Board of Directors has approved a regular quarterly dividend of $0.16 per share payable on January 25, 2019 to holders of record on December 28, 2018.
Danaher Corporation announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will be presenting at the Baird Global Industrial Conference in Chicago on Tuesday, November 6, 2018 at 9:30 a.m. CT.
Danaher Corporation today announced results for the third quarter 2018. For the quarter ended September 28, 2018, net earnings were $663.7 million, or $0.93 per diluted share which represents a 15.0% year-over-year increase.
Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will be presenting at the Morgan Stanley Global Healthcare Conference in New York City on Friday, September 14, 2018 at 8:45 a.m. ET.
Danaher Corporation announced results for the second quarter 2018.
Danaher Corporation announced its intention to spin off its Dental segment into an independent, publicly-traded company
Danaher Corporation announced that Daniel L. Comas, Executive Vice President and Chief Financial Officer, and Rainer Blair, Executive Vice President, will be presenting at the Jefferies Global Healthcare Conference
Danaher Corporation announced that Daniel L. Comas, Executive Vice President and Chief Financial Officer, and Rainer Blair, Executive Vice President, will be presenting at the Jefferies Global Healthcare Conference.
Danaher Corporation announced results for the first quarter 2018.
Companies that produce PCR products would be of interest to larger concerns given the need for better life sciences research and pharmaceutical pipelines.
Danaher Corporation announced that it expects first quarter 2018 adjusted diluted net earnings per share to be above the high-end of the Company's previously communicated guidance range.
Global In-Vivo Toxicology Market 2018-2022 with Thermo Fisher, Danaher, Charles River, Covance and The Jackson Laboratory Dominating - ResearchAndMarkets.com
The "In Vivo Toxicology Market by Product (Instruments, Consumables), (Animal models, Reagents & Kits), Testing type (Chronic, Sub-chronic), Toxicity Endpoints (Immunotoxicity, Systemic, DART), Testing Facility - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.